Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

• Status: Completed
• Trial end date: 2009-10-01

Summary

The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer

• Phase: Phase 2

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bevacizumab; Cediranib; Fluorouracil; Leucovorin; Oxaliplatin